Weetman A P, Gunn C, Hall R, McGregor A M
Clin Endocrinol (Oxf). 1985 Jan;22(1):57-64. doi: 10.1111/j.1365-2265.1985.tb01065.x.
Two recent studies have reported that antithyroid drugs inhibit killer (K) and natural killer (NK) cell function in vitro, which could be relevant to the changes in these cell populations during treatment of Graves' disease. In contrast to these reports we have found no in vitro effect of pharmacologically relevant concentrations of methimazole (MMI) (100 mumol/l) on (i) NK cell function using K562 cells or MOLT-4 cells as targets, (ii) K cell function using antibody-dependent cytotoxicity assays with L929 cells or thyroid-antigen-coated chick red cells, or (iii) monocyte-dependent cytotoxin-mediated killing of L929 cells. Enhanced cytotoxicity was found with 1 mmol/l MMI in some of these assays but this was not consistent since it occurred only in certain individual cultures. Since we have shown previously that 100 mumol/l MMI inhibits oxygen radical generation, the present results add to the evidence that these radicals are not directly involved in cell-mediated cytotoxicity and do not support the concept that antithyroid drugs have a significant effect on antibody-dependent cell-mediated cytotoxicity in Graves' disease.
最近的两项研究报告称,抗甲状腺药物在体外可抑制杀伤(K)细胞和自然杀伤(NK)细胞的功能,这可能与格雷夫斯病治疗期间这些细胞群体的变化有关。与这些报告相反,我们发现药理学相关浓度的甲巯咪唑(MMI)(100μmol/L)对以下方面无体外效应:(i)以K562细胞或MOLT-4细胞为靶细胞时的NK细胞功能;(ii)使用L929细胞或甲状腺抗原包被的鸡红细胞进行抗体依赖性细胞毒性试验时的K细胞功能;或(iii)单核细胞依赖性细胞毒素介导的对L929细胞的杀伤。在其中一些试验中,发现1mmol/L的MMI可增强细胞毒性,但这并不一致,因为仅在某些个体培养物中出现。由于我们之前已表明100μmol/L的MMI可抑制氧自由基的产生,目前的结果进一步证明这些自由基并不直接参与细胞介导的细胞毒性,也不支持抗甲状腺药物对格雷夫斯病中抗体依赖性细胞介导的细胞毒性有显著影响这一概念。